What is BBNX (BBNX) stock price today?

BBNX (BBNX) is currently trading at $15.90, up 12.69% today.

What is BBNX P/E ratio?

BBNX's P/E ratio is -6.53. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BBNX return on equity (ROE)?

BBNX's return on equity (ROE) is -25.35%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is BBNX's market cap?

BBNX has a market capitalization of $715.34M.

NASDAQ · Medical - Equipment & Services

BBNX (BBNX) Stock

$15.90 +12.69% NASDAQ: BBNX Healthcare

Valuation

Metric	Value
Price	$15.90
Market Cap	$715.34M
P/E Ratio	-6.53
P/B Ratio	1.83
P/S Ratio	4.78
EPS (TTM)	$0.00
52-Week High	$32.71
52-Week Low	$8.80
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-25.35%
ROA	-22.19%
ROCE	-25.00%
Gross Margin	-72.00%
Operating Margin	-72.00%
Net Margin	-60.27%
Debt/Equity	0.03
Current Ratio	8.65

Annual Financials (USD)

Metric	2022	2023	2024	2025
Revenue	$0	$12.0M	$65.0M	$100.0M
Operating Profit	$-66.0M	$-36.0M	$-45.0M	$-72.0M
Net Profit	$-65.0M	$-44.0M	$-55.0M	$-73.0M
EPS	$-12.96	$-8.31	$-8.60	$-1.81
Op Margin	-36784.4%	-298.9%	-69.5%	-71.5%

Balance Sheet (USD)

Metric	2022	2023	2024	2025
Total Assets	$36.0M	$110.0M	$150.0M	$329.0M
Total Liabilities	$23.0M	$51.0M	$74.0M	$41.0M
Cash	$28.0M	$27.0M	$30.0M	$32.0M
Borrowings	$4.0M	$4.0M	$7.0M	$7.0M

Latest News

Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating MT Newswires · Jul 13, 2026 Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026 GlobeNewswire · Jul 1, 2026 Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website GlobeNewswire · Jun 2, 2026 Beta Bionics to launch its first insulin patch pump to compete with Insulet MedTech Dive · May 26, 2026 Beta Bionics Expects Commercialization of Mint Insulin Patch Pump in 2027 MT Newswires · May 21, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025
Operating Cash Flow	$-60.0M	$-32.0M	$-48.0M	$-51.0M
Investing Cash Flow	$-2.0M	$-70.0M	$-7.0M	$-168.0M
Financing Cash Flow	$0	$101.0M	$0	$0
Net Cash Flow	$-4.0M	$-1.0M	$4.0M	$1.0M
Free Cash Flow	$-61.0M	$-33.0M	$-52.0M	$-56.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-11.60%
Quick Ratio	9.67
Interest Coverage	—
Return 1Y	9.21%
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AHCO	$11.17	-0.45%	8.52	$1.52B	0.00%
DVAXDynavax Technologies Corporation	$15.50	+0.00%	-40.79	$1.82B	0.00%
IMTX	$8.24	-4.52%	-4.98	$1.10B	0.00%
KMTS	$23.99	+5.08%	-3.85	$1.41B	0.00%
ORIC	$13.50	+4.41%	-5.39	$1.40B	0.00%

About BBNX

BBNX is led by CEO Sean T. Saint, employs 352 people, headquartered in US, publicly traded since 2025.

BBNX stock trades at $15.90 with a market capitalization of $715.34M. The stock is valued at a price-to-earnings (P/E) ratio of -6.53, price-to-book of 1.83, price-to-sales of 4.78. Over the past 52 weeks the stock has ranged between $8.80 and $32.71, and currently trades 51.4% below its 52-week high.

On profitability, BBNX generates a return on equity (ROE) of -25.35%, return on capital employed of -25.00%, an operating margin of -72.00%, a net profit margin of -60.27%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides